A case of myelodysplastic syndrome/myeloproliferative neoplasm (MDS/MPN) successfully treated with lenalidomide.
Lenalidomide is an immunomodulatory drug which is used to treat patients with MDS with deletion 5q chromosomal abnormality. In 2008, WHO introduced a new disease entity called MDS/MPN. No specific treatment for MDS/MPN subtype has yet been identified. We report a patient with MDS/MPN who responded well to lenalidomide therapy.
Division of Hematology/Oncology, Department of Medicine, Buffalo General Hospital Room E 318, Buffalo, New York, 14203, USA.
Anwarul
A
Islam
5q chromosomal abnormality; Lenalidomide; myelodysplastic syndrome; myelodysplastic syndrome/myeloproliferative neoplasm